These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36031547)

  • 21. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of abuse-deterrent formulations in countering opioid misuse and abuse.
    Nguyen V; Raffa RB; Taylor R; Pergolizzi JV
    J Clin Pharm Ther; 2015 Dec; 40(6):629-34. PubMed ID: 26595258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations.
    Wening K; Schwier S; Stahlberg HJ; Galia E
    J Opioid Manag; 2017; 13(6):473-484. PubMed ID: 29308593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.
    Setnik B; Schoedel KA; Levy-Cooperman N; Shram M; Pixton GC; Roland CL
    J Opioid Manag; 2017; 13(6):485-523. PubMed ID: 29308594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance.
    Zhao L; Li Z; Fang L; Kim MJ; Nallani SC; Sahajwalla CG; Calderon SN; Roca RA; Feng K; Zineh I; Lionberger R
    EClinicalMedicine; 2021 Nov; 41():101135. PubMed ID: 34585126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.
    Peacock A; Larance B; Bruno R; Pearson SA; Buckley NA; Farrell M; Degenhardt L
    Addiction; 2019 Mar; 114(3):389-399. PubMed ID: 29989247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.
    Mastropietro DJ; Omidian H
    Expert Opin Pharmacother; 2015 Feb; 16(3):305-23. PubMed ID: 25421961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abuse-deterrent opioid formulations: are they a pipe dream?
    Katz N
    Curr Rheumatol Rep; 2008 Jan; 10(1):11-8. PubMed ID: 18457606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.
    Walter C; Knothe C; Lötsch J
    Clin Pharmacokinet; 2016 Jul; 55(7):751-767. PubMed ID: 26719075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacists' role in addressing opioid abuse, addiction, and diversion.
    J Am Pharm Assoc (2003); 2014; 54(1):e5-15. PubMed ID: 24257743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abuse-deterrent formulations approval reform: Will clinical correctness or real-world results be used to address the nation's opioid crisis: "Noninterference" as a new approval standard.
    Cohen D
    J Opioid Manag; 2017; 13(6):357-362. PubMed ID: 29308582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.
    Miller CJ; Dart RC; Katz NP; Webster LR
    J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of abuse-deterrent opioids and recommendations for practical patient care.
    Adler JA; Mallick-Searle T
    J Multidiscip Healthc; 2018; 11():323-332. PubMed ID: 30026658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization.
    Petrilla A; Marrett E; Shen X; Kwong WJ; Pezalla E
    Am Health Drug Benefits; 2020 Feb; 13(1):21-31. PubMed ID: 32165996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community pharmacist-provided opioid intervention frequencies and barriers.
    Nichols MA; Kepley KL; Rosko KS; Hudmon KS; Curran GM; Ott CA; Snyder ME; Miller ML
    J Am Pharm Assoc (2003); 2023; 63(1):336-342. PubMed ID: 36369075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.